TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu · 2026
Read TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy by Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13294373.txt.
Description
Ziqiang Ding and coauthors build a nanobody T cell engager that can reach targets inside cancer cells in a 2026 proof-of-concept study. Standard engagers only grip surface markers because inner proteins stay hidden, and bulky fragments clump easily. Their two-headed nanobody joins T cells via CD3 while the other head mimics a T cell receptor, reading peptide scraps displayed on HLA-A2 from WT1 or GPC3 proteins.
Lab tests showed strict target-only T cell firing and killing, sparing marker-free cells. In mouse grafts from cell lines and patients, tumors shrank, survival lengthened, and T cell entry rose, with no reported treatment harms. A modular route to inner targets opens many cancers.
Catalog record
| CREATOR | Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50714 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |